Shun†lichi Kuroda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4996761/publications.pdf

Version: 2024-02-01

304743 361022 61 1,392 22 35 citations h-index g-index papers 65 65 65 1443 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Bio-nanocapsules for oriented immobilization of DNA aptamers on aptasensors. Analyst, The, 2022, 147, 489-495.	3 . 5	2
2	Binding of Hepatitis B Virus Pre-S1 Domain-Derived Synthetic Myristoylated Peptide to Scavenger Receptor Class B Type 1 with Differential Properties from Sodium Taurocholate Cotransporting Polypeptide. Viruses, 2022, 14, 105.	3.3	1
3	Engineering of Extracellular Vesicles for Small Molecule-Regulated Cargo Loading and Cytoplasmic Delivery of Bioactive Proteins. Molecular Pharmaceutics, 2022, 19, 2495-2505.	4.6	10
4	A regulatory role of scavenger receptor class B type 1 in endocytosis and lipid droplet formation induced by liposomes containing phosphatidylethanolamine in HEK293T cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 118859.	4.1	5
5	Real-Time Luminescence Assay for Cytoplasmic Cargo Delivery of Extracellular Vesicles. Analytical Chemistry, 2021, 93, 5612-5620.	6.5	31
6	Id2 Represses Aldosterone-Stimulated Cardiac T-Type Calcium Channels Expression. International Journal of Molecular Sciences, 2021, 22, 3561.	4.1	4
7	Polymerized Albumin Receptor of Hepatitis B Virus for Evading the Reticuloendothelial System. Pharmaceuticals, 2021, 14, 408.	3.8	1
8	HBV Pre-S1-Derived Myristoylated Peptide (Myr47): Identification of the Inhibitory Activity on the Cellular Uptake of Lipid Nanoparticles. Viruses, 2021, 13, 929.	3.3	4
9	Binding of liposomes composed of phosphatidylcholine to scavenger receptor class B type 1 and its modulation by phosphatidic acid in HEK293T cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 119043.	4.1	6
10	Binding of Nanoparticles Harboring Recombinant Large Surface Protein of Hepatitis B Virus to Scavenger Receptor Class B Type 1. Viruses, 2021, 13, 1334.	3.3	5
11	Reporter gene assay for membrane fusion of extracellular vesicles. Journal of Extracellular Vesicles, 2021, 10, e12171.	12.2	21
12	Two-dimensional membrane scaffold for the oriented immobilization of biosensing molecules. Biosensors and Bioelectronics, 2020, 150, 111860.	10.1	7
13	Influence of Nivolumab for Intercellular Adhesion Force between a T Cell and a Cancer Cell Evaluated by AFM Force Spectroscopy. Sensors, 2020, 20, 5723.	3.8	2
14	Digital Pathology Platform for Respiratory Tract Infection Diagnosis via Multiplex Single-Particle Detections. ACS Sensors, 2020, 5, 3398-3403.	7.8	21
15	A Novel Hybrid Drug Delivery System for Treatment of Aortic Aneurysms. International Journal of Molecular Sciences, 2020, 21, 5538.	4.1	17
16	Enhanced sugar chain detection by oriented immobilization of Fc-fused lectins. Bioscience, Biotechnology and Biochemistry, 2020, 84, 1775-1779.	1.3	3
17	Virus-mimicking nanocarriers for the intracellular delivery of therapeutic biomolecules. Nanomedicine, 2020, 15, 1163-1165.	3.3	3
18	Development of a universal method for the measurement of binding affinities of antibody drugs towards a living cell based on AFM force spectroscopy. Analytical Methods, 2020, 12, 2922-2927.	2.7	8

#	Article	IF	CITATIONS
19	Construction of a Macrophage-Targeting Bio-nanocapsule-Based Nanocarrier. Methods in Molecular Biology, 2020, 2059, 299-313.	0.9	1
20	The Structural Function of Nestin in Cell Body Softening is Correlated with Cancer Cell Metastasis. International Journal of Biological Sciences, 2019, 15, 1546-1556.	6.4	23
21	In vivouterine local gene delivery system using TATâ€displaying bionanocapsules. Journal of Gene Medicine, 2019, 21, e3140.	2.8	3
22	A hepatitis B virus-derived human hepatic cell-specific heparin-binding peptide: identification and application to a drug delivery system. Biomaterials Science, 2019, 7, 322-335.	5.4	13
23	Induction of lipid droplets in non-macrophage cells as well as macrophages by liposomes and exosomes. Biochemical and Biophysical Research Communications, 2019, 510, 184-190.	2.1	10
24	High-throughput single nanoparticle detection using a feed-through channel-integrated nanopore. Nanoscale, 2019, 11, 20475-20484.	5.6	10
25	Oriented immobilization to nanoparticles enhanced the therapeutic efficacy of antibody drugs. Acta Biomaterialia, 2019, 86, 373-380.	8.3	14
26	Development of a macrophage-targeting and phagocytosis-inducing bio-nanocapsule-based nanocarrier for drug delivery. Acta Biomaterialia, 2018, 73, 412-423.	8.3	26
27	Low immunogenic bio-nanocapsule based on hepatitis B virus escape mutants. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 595-600.	3.3	7
28	CD11c-specific bio-nanocapsule enhances vaccine immunogenicity by targeting immune cells. Journal of Nanobiotechnology, 2018, 16, 59.	9.1	20
29	Synthesis and assembly of Hepatitis B virus envelope protein-derived particles in Escherichia coli. Biochemical and Biophysical Research Communications, 2017, 490, 155-160.	2.1	5
30	A New Cell Separation Method Based on Antibody-Immobilized Nanoneedle Arrays for the Detection of Intracellular Markers. Nano Letters, 2017, 17, 7117-7124.	9.1	25
31	Scaffolds for oriented and close-packed immobilization of immunoglobulins. Biosensors and Bioelectronics, 2017, 89, 810-821.	10.1	34
32	Current Progress of Virus-mimicking Nanocarriers for Drug Delivery. Nanotheranostics, 2017, 1, 415-429.	5.2	47
33	Release of siRNA from Liposomes Induced by Curcumin. Journal of Nanotechnology, 2016, 2016, 1-6.	3.4	5
34	Bioâ€nanocapsuleâ€based scaffold improves the sensitivity and ligandâ€binding capacity of mammalian receptors on the sensor chip. Biotechnology Journal, 2016, 11, 805-813.	3.5	6
35	Mutational analysis of hepatitis B virus pre-S1 (9–24) fusogenic peptide. Biochemical and Biophysical Research Communications, 2016, 474, 406-412.	2.1	10
36	Cellular uptake of hepatitis B virus envelope L particles is independent of sodium taurocholate cotransporting polypeptide, but dependent on heparan sulfate proteoglycan. Virology, 2016, 497, 23-32.	2.4	32

#	Article	IF	CITATIONS
37	Potential of a non-cationic liposomes-based delivery system for nucleic acid medicines. Drug Delivery System, 2016, 31, 35-43.	0.0	1
38	Bio-nanocapsules displaying various immunoglobulins as an active targeting-based drug delivery system. Acta Biomaterialia, 2016, 35, 238-247.	8.3	10
39	Elucidation of the early infection machinery of hepatitis B virus by using bio-nanocapsule. World Journal of Gastroenterology, 2016, 22, 8489.	3.3	8
40	Virosomes of hepatitis B virus envelope L proteins containing doxorubicin: synergistic enhancement of human liver-specific antitumor growth activity by radiotherapy. International Journal of Nanomedicine, 2015, 10, 4159.	6.7	13
41	Intracellular trafficking of bio-nanocapsule–liposome complex: Identification of fusogenic activity in the pre-S1 region of hepatitis B virus surface antigen L protein. Journal of Controlled Release, 2015, 212, 10-18.	9.9	22
42	Development of a virus-mimicking nanocarrier for drug delivery systems: The bio-nanocapsule. Advanced Drug Delivery Reviews, 2015, 95, 77-89.	13.7	52
43	A bioâ€nanocapsule containing envelope protein domain <scp>III</scp> of Japanese encephalitis virus protects mice against lethal Japanese encephalitis virus infection. Microbiology and Immunology, 2013, 57, 470-477.	1.4	8
44	Nano-visualization of oriented-immobilized IgGs on immunosensors by high-speed atomic force microscopy. Scientific Reports, 2012, 2, 790.	3.3	39
45	Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells. International Journal of Nanomedicine, 2012, 7, 3341.	6.7	12
46	Hepatitis B virus envelope L protein-derived bio-nanocapsules: Mechanisms of cellular attachment and entry into human hepatic cells. Journal of Controlled Release, 2012, 160, 322-329.	9.9	23
47	Efficient and rapid purification of drug- and gene-carrying bio-nanocapsules, hepatitis B virus surface antigen L particles, from Saccharomyces cerevisiae. Protein Expression and Purification, 2011, 78, 149-155.	1.3	33
48	Fluorophore-labeled nanocapsules displaying IgG Fc-binding domains for the simultaneous detection of multiple antigens. Biomaterials, 2011, 32, 9011-9020.	11.4	23
49	Nanocapsules incorporating IgG Fc-binding domain derived from Staphylococcus aureus protein A for displaying IgGs on immunosensor chips. Biomaterials, 2011, 32, 1455-1464.	11.4	59
50	Human Liver-Specific Nanocarrier in a Novel Mouse Xenograft Model Bearing Noncancerous Human Liver Tissue. European Surgical Research, 2011, 46, 65-72.	1.3	9
51	Bionanocapsule-based enzyme–antibody conjugates for enzyme-linked immunosorbent assay. Analytical Biochemistry, 2010, 396, 257-261.	2.4	28
52	Nanoparticles for human liver-specific drug and gene delivery systems: <i>in vitro</i> and <i>in vivo</i> advances. Expert Opinion on Drug Delivery, 2009, 6, 39-52.	5.0	41
53	Role of the T-Type Calcium Channel Ca _V 3.2 in the Chronotropic Action of Corticosteroids in Isolated Rat Ventricular Myocytes. Endocrinology, 2009, 150, 3726-3734.	2.8	35
54	Bio-Nanocapsule–Liposome Conjugates for In Vivo Pinpoint Drug and Gene Delivery. Methods in Enzymology, 2009, 464, 147-166.	1.0	21

#	Article	IF	CITATION
55	Bio-nanocapsule conjugated with liposomes for in vivo pinpoint delivery of various materials. Journal of Controlled Release, 2008, 126, 255-264.	9.9	67
56	Enigma homolog 1 scaffolds protein kinase D1 to regulate the activity of the cardiac L-type voltage-gated calcium channel. Cardiovascular Research, 2008, 78, 458-465.	3.8	34
57	Characterization of bio-nanocapsule as a transfer vector targeting human hepatocyte carcinoma by disulfide linkage modification. Journal of Controlled Release, 2007, 118, 348-356.	9.9	17
58	The specific delivery of proteins to human liver cells by engineered bio-nanocapsules. FEBS Journal, 2005, 272, 3651-3660.	4.7	32
59	Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nature Biotechnology, 2003, 21, 885-890.	17.5	245
60	Size distribution measurement of vesicles by atomic force microscopy. Analytical Biochemistry, 2002, 309, 196-199.	2.4	48
61	Physicochemical and immunological characterization of hepatitis B virus envelope particles exclusively consisting of the entire L (pre-S1+pre-S2+S) protein. Vaccine, 2001, 19, 3154-3163.	3.8	66